HOME>News Release

News Release

  • Mitsubishi Tanabe Pharma
  • Former TANABE SEIYAKU
  • Former Mitsubishi Pharma
  • RSS
  • About RSS

2017

June 20
Fingolimod Hydrochloride wins Patent Infringement Lawsuit in the U.S. District CourtPDF
June 1
Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund’s second phase ―Targeting treatments for infectious diseases that burden the developing world―PDF
May 18
Approval for partial change in administration / dosage for Crohn’s disease for REMICADE for I.V. Infusion 100, an anti-human TNFα monoclonal antibodyPDF
May 16
Mitsubishi Tanabe Pharma announces The Lancet Neurology publication of the positive clinical results of Edaravone for ALSPDF
May 10
Differences Between Non-Consolidated Actual Results for FY2015 and FY2016PDF
May 10
Announcement of Financial Results for FY2016
⇒R&D Pipeline "State of New Product Development"
May 10
Notice of Dividend of Retained EarningsPDF
May 10
Notice Regarding Revision of Business Structure for Recombinant Human Serum Albumin PreparationPDF
May 9
Establishment of Vaccine Manufacturing Joint Venture: BIKEN CO.,Ltd.PDF
May 8
New Japan-originated ALS treatment option available to patients in the U.S. ―U.S. FDA approves RADICAVA (edaravone) for the treatment of ALSPDF
April 26
Introduction of Performance-Linked Stock Compensation Plan for Board DirectorsPDF
April 24
Mitsubishi Tanabe Pharma Group receives import and marketing permission in Taiwan for CANAGLU Tablets 100mg, a treatment agent for type 2 diabetes mellitusPDF
April 17
Notice regarding overseas subsidiary MT Pharma (Thailand) Strengthening business development in the ASEAN regionPDF
March 30
Notice regarding approval of indication of ulcerative colitis and additional formulation for SIMPONI subcutaneous injection 50mg syringe (generic name: golimumab), a human monoclonal antibody specific for human TNF αPDF
March 29
Mitsubishi Tanabe Pharma and Daiichi Sankyo to Expand Strategic Alliance in the Diabetes Field The companies enter into a marketing alliance agreement for MT-2412, a combination drug for the treatment of type 2 diabetes mellitus, following co-operation for TENELIA Tablets, a selective DPP-4 inhibitor, and CANAGLU Tablets, an SGLT2 inhibitorPDF
March 28
Split off and transfer of Generic Drugs and Part of Long-Listed Products Business and Change of SubsidiaryPDF
February 6
Announcement of FY2016 3rd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
February 3
Mitsubishi Tanabe Pharma Corporation Strategically Strengthens Its Foundation in the Field of Inflammatory Bowel Disease Mitsubishi Tanabe Pharma signs co-promotion agreement with Janssen Pharmaceutical K.K. for STELARA for an indication of Crohn’s diseasePDF
January 27
Biogen and Mitsubishi Tanabe Pharma Terminate the License Agreement on MT-1303PDF

2016

November 7
Basic Agreement on the Establishment of a Joint VenturePDF
November 1
Announcement of FY2016 2nd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
November 1
Mitsubishi Tanabe Pharma Takes on the Challenge of Cell Therapy with the Conclusion of an Invossa Licensing Agreement with Kolon Life Science Aiming for therapy that addresses unmet medical needs in the treatment of knee osteoarthritisPDF
October 25
Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2017PDF
October 5
Joint research identifies hit compounds for the development of a new treatment for malaria Mitsubishi Tanabe Pharma uses its compound library in joint research activities with Medicines for Malaria Venture ―Targeting treatments for infectious diseases that burden the developing world―PDF
October 4
Execution of Basic Agreement for Sales Anti-Allergy Agent, Rupatadine TabletsPDF
September 6
Application for partial change in administration/dosage for Crohn's disease for REMICADE for I.V. Infusion 100, an anti-human TNFα monoclonal antibodyPDF
August 30
FDA Accepts Mitsubishi Tanabe Pharma’s NDA Filing for Edaravone to Treat ALSPDF
August 26
Valixa Tablet 450mg Approval for Additional Indication in Japan for the Prevention of CMV disease in organ transplant patientsPDF
August 23
Application filed in Japan fortype 2 diabetes mellitus treatment agent combination drug - Combination of selective DPP-4 inhibitor TENELIA Tablets and SGLT2 inhibitor CANAGLU Tablets -PDF
August 2
Announcement of FY2016 1st Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
June 22
Regarding Nomination Committee and Compensation CommitteePDF
June 20
Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United StatesPDF
June 6
Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology FundPDF
May 13
Approval of REMICADE for I.V. Infusion 100, an Anti-Human TNFα Monoclonal Antibody, for a Partial Change in Dosage and Usage in PsoriasisPDF
May 13
Corrections with respect to “Summary of Financial Results for year ended March 31, 2016” (Japan GAAP) (Consolidated)PDF
May 11
Announcement of Financial Results for FY2015
⇒R&D Pipeline "State of New Product Development"
May 11
Notice of Dividend of Retained EarningsPDF
April 27
Change of Representative Director, Director and Corporate AuditorPDF
April 4
MT Pharma Singapore Pte. Ltd. Starts Business Operations Mitsubishi Tanabe Pharma's Subsidiary in SingaporePDF
March 29
Astellas and Mitsubishi Tanabe Pharma Execute Agreement for Share of Compound LibrariesPDF
March 22
Valixa Tablet 450 mg Application for Additional Indication in Japan for the Prevention of CMV disease in organ transplant patients Public Knowledge-based ApplicationPDF
March 10
Notice regarding change of current commercialization scheme to new strategic co-promotion partnership in Japan for RA treatment agent Simponi subcutaneous injection 50 mg syringe (generic name: golimumab)PDF
February 23
Mitsubishi Tanabe Pharma Enhances Operations in the United StatesPDF
February 3
Announcement of FY2015 3rd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
February 3
Notice Regarding Results of Early Retirement ProgramPDF

News Release

ReadSpeaker docReader makes documents accessible to all users including users with vision problems letting users view and listen to texts.
User guide